The FDA has approved dupilumab for the treatment of eosinophilic esophagitis (EoE) in children aged 1-11 years and weighing ≥ 15 kg. Dupilumab is the first and only medicine approved for this use. EoE is a chronic inflammatory disorder that damages the esophagus, causing difficulty swallowing and eating. The approval is based on results from a phase 3 trial, which showed that 66% of children who received higher dose dupilumab achieved disease remission, compared to 3% of those who received a placebo. The most common adverse events were injection site reactions, upper respiratory tract infections, arthralgia, and herpes viral infections.
Source link
FDA Expands Dupilumab for EoE to Younger Children

Share This Article